103750-03-4

Usage

Uses

Used in Biochemistry and Molecular Biology:
5-Maleimidovaleric acid-NHS is used as a labeling agent for the primary amines (-NH2) of proteins, amine-modified oligonucleotides, and other amine-containing molecules. The NHS ester reacts with the amine group, forming a stable amide bond, which allows for the covalent attachment of the molecule to the target biomolecule.
Used in Protein Modification:
5-Maleimidovaleric acid-NHS is used as a protein modification agent to introduce a reactive maleimide group into proteins. This maleimide group can then react with a thiol group present in another biomolecule, forming a covalent bond and enabling the connection of the two biomolecules. This property is particularly useful in the study of protein-protein interactions and the development of protein conjugates for various applications.
Used in Drug Delivery Systems:
In the pharmaceutical industry, 5-Maleimidovaleric acid-NHS can be used as a component in the development of drug delivery systems. The maleimide group can be used to attach drug molecules or drug carriers to specific targeting molecules, such as antibodies or peptides, enabling the selective delivery of therapeutic agents to specific cells or tissues.
Used in Diagnostics:
5-Maleimidovaleric acid-NHS can be employed in the development of diagnostic tools, such as immunoassays and biosensors. The maleimide group can be used to attach signaling molecules, like fluorescent dyes or enzymes, to antibodies or other recognition elements, allowing for the detection and quantification of specific analytes in biological samples.
Used in Materials Science:
In the field of materials science, 5-Maleimidovaleric acid-NHS can be utilized to functionalize various surfaces, such as nanoparticles or polymers, with specific biomolecules. This can be useful for the development of biocompatible materials, drug delivery systems, or sensors with enhanced specificity and sensitivity.

Upstream product

• 6066-82-6 1-hydroxy-pyrrolidine-2,5-dione 
• 57078-99-6 5-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)pentanoic acid 
• 91420-49-4 tert-butyl 2-hydroxyethylpropionate 

Downstream Products

• 143230-95-9 C₄₅H₅₅F₂N₇O₁₀ 

Relevant academic research and scientific papers

Conjugate of cytotoxin molecule and cell binding receptor molecule

A conjugate of a strong cytotoxin molecule and a cell binding receptor molecule has a structure shown in a molecular formula (I), wherein T, L, m, n, -----, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12 and R13 are defined in the text. The conjugate is used for treating cancer, immunological diseases and infectious diseases.

CONJUGATE OF CELL-BINDING RECEPTOR WITH CYTOTOXIC AGENT

PROBLEM TO BE SOLVED: To provide a conjugate of a potent cytotoxic agent with a cell-surface receptor binding molecule for targeted treatment. SOLUTION: According to the present invention, there is provided a conjugate having a structure of formula (I) and a pharmaceutical acceptable salt and a solvate thereof. The conjugate is used for treating cancer, autoimmune disease, and infectious disease. (T is a targeting or binding ligand; L is a releasable linker; a broken line is a linkage bond that L connects to a molecule inside the bracket independently; n is an integer of 1 to 20; m is an integer of 1 to 10; and a structure in parentheses is a potent antimitotic agent/drug.) SELECTED DRAWING: None COPYRIGHT: (C)2017,JPOandINPIT

CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS

A conjugate of a potent cytotoxic agent with a cell-surface receptor binding molecule having a formula (I), wherein T, L, m, n, Y, R1, R2, R3, R4, R5, R6, R7, R8, Rsu

Conjugates of Cell Binding Molecules with Cytotoxic Agents

A conjugate of a potent cytotoxic agent with a cell-surface receptor binding molecule having a Formula (I), wherein T, L, m, n, R1, R2, R3, R4, R5, R6, R7, R8, R9

Syntheses of siderophore-drug conjugates using a convergent thiol-maleimide system

Three siderophore-drug conjugates (sideromycins) were synthesized by preparation of a maleimide linked derivative of the siderophore desferrioxamine B and reacting the corresponding Ga3+-complex with freshly prepared thiol-containing antibiotics: loracarbef, ciprofloxacin, and nadifloxacin. The conjugates and their synthetic precursors were tested against a broad panel of bacteria and were found to display Gram-positive selective, growth inhibitory activity (μM), indicating that this approach is suitable for the convergent syntheses and screening of novel sideromycins.